Zackary Falls,1,* Xueqing Zhang,2,* Peter L Elkin,1 David Jacobs,3 Edward M Bednarczyk,4 Walter Gibson,4 Gail P Jette,5 Kenneth E Leonard6,* 1Department of Biomedical Informatics and Clinical and Research Institute on Addiction, University at
Falls Z +7 more
doaj
Integrating HIV prevention services into care settings for people with opioid use disorder (OUD): a study protocol for implementation strategy development and modeling. [PDF]
Gu M +7 more
europepmc +1 more source
A GWAS Meta-meta-analysis and In-depth Silico Pharmacogenomic Investigations in Identification of APOE and Other Genes Associated with Pain, Anti-inflammatory, and Immunomodulating Agents in Opioid Use Disorder (OUD) Derived from 14.91 M Subjects. [PDF]
Sharafshah A +6 more
europepmc +1 more source
Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes. [PDF]
Hammerslag LR +8 more
europepmc +1 more source
Network Analysis of Medical Claims Data Suggests Network-Based, Regional Targeting and Intervention Delivery Strategies to Increase Access to Office Based Opioid Treatment (OBOT) for Opioid Use Disorder (OUD). [PDF]
Green HD, Kaminski PC.
europepmc +1 more source
County-level context and differential policy impacts on buprenorphine use among medicaid enrollees with opioid use disorder in Kentucky, 2018-2025. [PDF]
Miracle DK +3 more
europepmc +1 more source
Do We Really Need to Continue Pharmacotherapy for Opioid Use Disorder (OUD) Indefinitely?
Rajendra D. Badgaiyan +2 more
openaire +1 more source
Long-Acting Injectable Buprenorphine in Pregnancy. [PDF]
Nacev EC +5 more
europepmc +1 more source
Infections and the Opioid Epidemic: Changing Epidemiology and Treatment Options. [PDF]
Fanucchi LC +3 more
europepmc +1 more source

